Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04434482
Title IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Impact Therapeutics, Inc.
Indications

ovarian cancer

castration-resistant prostate carcinoma

prostate cancer

Advanced Solid Tumor

triple-receptor negative breast cancer

lung small cell carcinoma

Therapies

Senaparib + Temozolomide

Age Groups: adult | senior
Covered Countries

Facility Status City State Zip Country Details
Border Medical Centre Recruiting Albury New South Wales 2640 Australia Details
Blacktown Hospital Recruiting Blacktown New South Wales 2148 Australia Details
Orange Hospital Recruiting Orange New South Wales 2800 Australia Details
Peninsula Health Not yet recruiting Frankston Victoria 3199 Australia Details
Chungbuk National University Hospital Not yet recruiting Cheongju-si 2864 Korea, Republic of Details
The Catholic university of Korea, st. Vincent's Hospital Recruiting Gyeonggi-do 16247 Korea, Republic of Details
Yonsei university health system, Severance Hospital Not yet recruiting Seoul 03722 Korea, Republic of Details
Asan Medical Center Not yet recruiting Seoul 05505 Korea, Republic of Details
China Medical University Hospital Recruiting Taichung 404 Taiwan Details
National Cheng Kung University Hospital Not yet recruiting Tainan 704 Taiwan Details
Chi Mei Medical Center Recruiting Tainan 73657 Taiwan Details
National Taiwan University Hospital Recruiting Taipei 100 Taiwan Details
Chang Gung Medical Foundation Linko Not yet recruiting Taoyuan 333 Taiwan Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field